Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting
Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.